NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc.

American Century Companies Inc. lifted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 17.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 624,285 shares of the company’s stock after acquiring an additional 91,369 shares during the period. American Century Companies Inc. owned 0.55% of NewAmsterdam Pharma worth $17,755,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of NAMS. Atle Fund Management AB grew its position in NewAmsterdam Pharma by 23.2% in the 3rd quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock worth $5,507,000 after purchasing an additional 36,402 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after buying an additional 1,252,451 shares during the last quarter. Keybank National Association OH bought a new stake in shares of NewAmsterdam Pharma during the third quarter valued at approximately $455,000. Franklin Resources Inc. boosted its position in shares of NewAmsterdam Pharma by 30.6% during the second quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after buying an additional 78,300 shares during the period. Finally, Handelsbanken Fonder AB grew its holdings in NewAmsterdam Pharma by 18.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock worth $11,541,000 after buying an additional 64,200 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Key Stories Impacting NewAmsterdam Pharma

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: Several sell‑side firms have raised ratings and targets (Needham raised its target to $48, HC Wainwright upgraded to strong‑buy, RBC lifted its target to $47) and the consensus remains a “Moderate Buy” with an average target near $47, supporting upside expectations.
• Positive Sentiment: Large institutional positions and recent accumulation (Capital World Investors, Jennison, Duquesne and others increased stakes) signal continuing institutional confidence and provide potential buying support under the stock.
• Neutral Sentiment: Recent profile/coverage updates (e.g., Barron’s stock page) provide visibility but do not contain new material clinical or financial news likely to immediately change fundamentals. Barron’s stock page
• Negative Sentiment: Large, repeated insider sales by CFO/insider Johannes Jacob Piete Kastelein (multiple trades on March 5–9–6 totaling several hundred thousand shares and reducing his stake by roughly ~57–60%) are material — such concentrated selling can pressure the stock and raise investor concern about insider liquidity needs or sentiment. InsiderTrades: Kastelein sales SEC filing
• Negative Sentiment: Director Louis G. Lange sold 28,186 shares (March 6), another disclosed insider sale that adds to the net insider selling narrative. SEC filing
• Negative Sentiment: Recent quarterly results (Feb. 18) showed an EPS miss and very limited revenue, with negative margins — underlying fundamentals remain loss‑making, which keeps the stock sensitive to sentiment and execution risk.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NAMS. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Needham & Company LLC increased their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Guggenheim upped their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, The Goldman Sachs Group increased their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.10.

NewAmsterdam Pharma Stock Performance

NAMS opened at $31.27 on Wednesday. The company has a market capitalization of $3.60 billion, a PE ratio of -18.08 and a beta of 0.04. The stock’s fifty day moving average is $33.41 and its 200-day moving average is $33.36. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. On average, equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 32,612 shares of the stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $774,425.40. This represents a 57.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis G. Lange sold 28,186 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.41, for a total transaction of $828,950.26. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,422,314 shares of company stock valued at $47,090,707 over the last quarter. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.